Recombinant Human NKp30 / NCR3 / CD337 Protein, His Tag, 100 µg

Background
Natural cytotoxicity triggering receptor 3 (NCR3) is also known as Activating natural killer receptor p30, Natural killer cell p30-related protein (NK-p30), CD antigen CD337, 1C7, LY117. NCR3 /CD337 /NKp30 belongs to the natural cytotoxicity receptor (NCR) family. NCR3 /NKp30 contains one Ig-like (immunoglobulin-like) domain. NCR3 /NKp30 is selectively expressed by all resting and activated NK cells and weakly expressed in spleen. NCR3 is homodimer in the unliganted form. NCR3 interacts with CD3Z. NCR3 interacts with and is activated by binding to NCR3LG1 or BAG6. Engagement of NCR3 by BAG6 also promotes dendritic cell (DC) maturation, both through killing those DCs that did not properly acquire a mature phenotype, and inducing NK cells to release TNFA and IFNG, which promotes DC maturation.

Source
Recombinant Human NKp30 protein, His Tag (NC3-H5228) is expressed from human 293 cells (HEK293). It contains AA Leu 19 - Gly 135 (Accession # AAH52582).
Predicted N-terminus: Leu 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 13.7 kDa. The protein migrates as 21-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1)  "Natural Killer Cell Receptors and Endometriosis: A Systematic Review"
Reis, Rosa, Ângelo-Dias et al
Int J Mol Sci (2022) 24 (1)
(2)  "Identification of the CD16low CD56low CD38pos Natural Killer Cell as a Key Subset in Patients with Multiple Myeloma"
Chen, Yu
Iran J Immunol (2022) 19 (4), 358-368
(3)  "Janus kinase inhibitors alter NK cells phenotype and inhibit their antitumor capacity"
Meudec, Richebé, Pascaud et al
Rheumatology (Oxford) (2022)
Showing 1-3 of 713 papers.